TNZTP Fair Value & Analysis
Healthcare · TR · Market cap 11.3B TRY
Fair value as of: Aug 2, 2026
From 26 valuation models · updated today
Share price +14.2% over the past month.
A solid business, but the price sits 19% above our fair value.
What matters now
- Solid but not exceptional quality (54/100) and above fair value, neither a clear bargain nor a standout compounder.
- A fairly wide model range (15.30 TRY to 30.44 TRY) leaves room in how you read the outcome.
Price vs Fair Value (4 years)
White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Aug 2, 2026.
How to read this chart
43‑month range 3.55 TRY – 32.99 TRY · fair‑value band 15.30 TRY – 30.44 TRY · the 28.32 TRY price screens above the 22.82 TRY fair value. Dashed = 300-day average. As of Aug 2, 2026.
Analysis
TNZTP (TNZTP) currently trades at 28.32 TRY, while our model-based Fair Value estimate is 22.82 TRY, implying the stock looks roughly 19.4% overvalued today. We read business quality at 54/100 (solid quality), in the Healthcare sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium, the entry price still matters most (evidence: high).
Over the trailing twelve months, TNZTP generated revenue of 3.5B TRY at a net margin of 19.7%. Revenue grew 3.0% year over year. It earns a return on equity of 9.1%. The stock trades on a trailing P/E of 16.7. Fundamentals as of Aug 2, 2026
Our scenario range runs from 15.30 TRY (bear case) to 30.44 TRY (bull case); at 28.32 TRY, the current price sits within that range. The share trades about 15% below its 52-week high and 41% above its 52-week low, currently above its 200-day average. For context, the median of 10 Healthcare peers we cover trades at 11% fair-value upside, at -19%, TNZTP screens richer than that median.
Fair Value models
Each model estimates fair value its own way; the Fair Value above is the evidence-weighted blend. Evidence (0–100) measures how completely this model’s inputs are available: well-fed models carry more weight in the blend. The spread across models is intentional, each one stresses a different value driver; dividend models, for instance, come out structurally low when payout is small.
All 26 models by family
Widest divergence: Growth Earnings (78.44 TRY) versus Dividend Discount (2.52 TRY). Highest evidence: Growth DCF (80).
Key figures & financial health
More key figures
Figures from reported company fundamentals · as of Aug 2, 2026. TTM = trailing twelve months.
Quality Score breakdown
Of which business quality 53 · Market factors (momentum, volatility) 49
Non-valuation factor families (profitability, growth, cashflow, financial strength, momentum …), each academically grounded. Valuation itself sits in the Fair Value and is deliberately excluded here to avoid double-counting.
About the company
Tapdi Oksijen Özel Saglik ve Egitim Hizmetleri Sanayi Ticaret A.S. provides various health services in Turkey. It operates hospitals under the Izmir Tinaztepe University Private Buca Hospital, Tinaztepe Torbali Hospital, Tinaztepe Buca Medical Center, and Izmir Tinaztepe University Private Galen Hospital names.
Full company description
Tapdi Oksijen Özel Saglik ve Egitim Hizmetleri Sanayi Ticaret A.S. provides various health services in Turkey. It operates hospitals under the Izmir Tinaztepe University Private Buca Hospital, Tinaztepe Torbali Hospital, Tinaztepe Buca Medical Center, and Izmir Tinaztepe University Private Galen Hospital names. The company also provides various services in areas, such as anesthesia and reanimation; biochemistry; brain and nerve surgery; cardiology, cardiology intensive care, cardiovascular surgery, cosmetic, plastic, and reconstructive surgery; dermatology; ear, nose, throat, endocrinology, eye diseases, and emergency; family medicine; gastroenterology, general intensive care, general surgery, genetic diagnosis center, and gynecology and obstetrics; and hematology. In addition, it provides Internal medicine and interventional radiology; medical oncology and microbiology; neonatal intensive care, neurology, nuclear medicine, and nutrition and dietetics; oral and dental health, and orthopedics and traumatology; pathology, pediatric neurology, pediatric surgery, pediatrics, perinatology, physical therapy and rehabilitation, psychiatry, psychology, and pulmonary diseases; radiation oncology and radiology; and urology services. The company was founded in 1999 and is headquartered in Izmir, Turkey.
Company description, as reported by the company or data provider.
Revenue & earnings trend
FY2021 – FY2025 · reported fiscal years
TNZTP reported revenue of 3.4B TRY in FY2025 versus 310M TRY in FY2021, a compound +82.4%/yr. Reported net income was 696M TRY in FY2025, compounding +80.3%/yr from FY2021.
TNZTP sits 19% above fair value. Compare with HCA Healthcare, Inc →
Peer Group
Medical Care Facilities · 270 stocks
How this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.
Valuation Multiples vs Medical Care Facilities median · lower = cheaper
Snowflake
Five quick dimensions, each 0 to 100: VALUE (fair-value potential), FUTURE (revenue growth), PAST (return on equity), HEALTH (low debt), DIVIDEND (yield). Green = this stock, grey = typical sector peer.
Values & ESG
Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.
ESG scores are not available for this stock yet. Values and ESG data are contextual and can differ between providers.
Similar stocks
10 more Medical Care Facilities stocks, each showing price versus our Fair Value estimate (as of Aug 2, 2026).
| Stock | Price | Fair Value | vs Fair Value |
|---|---|---|---|
| HCA Healthcare, Inc HCA | $378.85 | $554.93 | +46% |
| Fresenius SE FRE | €41.73 | €32.15 | -23% |
| Dr. Sulaiman Al Habib Medical Services Group 4013 | 235.00 SAR | 112.37 SAR | -52% |
| IHH Healthcare Berhad, an investment holding company, Q0F | 2.76 SGD | 1.28 SGD | -54% |
| Tenet Healthcare Corporation THC | $194.91 | $338.05 | +73% |
| Rede D'Or São Luiz S.A RDOR3 | R$36.01 | R$47.31 | +31% |
| DaVita Inc DVA | $231.61 | $255.97 | +11% |
| Apollo Hospitals Enterprise Limited APOLLOHOSP | ₹8,841 | ₹2,908 | -67% |
| Fresenius Medical Care AG FMS | $24.68 | $45.60 | +85% |
| Aier Eye Hospital Group 300015 | ¥8.68 | ¥7.67 | -12% |
Compare TNZTP with another stock
Price, fair value, quality and upside side by side.
Explore undervalued stocks
More undervalued Healthcare stocks →
Frequently asked questions
Is TNZTP overvalued or undervalued?
What is the fair value of TNZTP?
What is the quality score of TNZTP?
What is the revenue of TNZTP?
What is the net profit margin of TNZTP?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data, nothing guessed.
Track TNZTP and try Pro for 14 days
One email gets you 14 days of full Pro (review alerts, the 35,000+ stock screener, the diversification check) plus the monthly Top-25 report of the most undervalued quality stocks. No card, cancel anytime.
Zero risk: nothing is ever charged. After 14 days you decide whether to stay.